Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) kicked off on Monday, up 28.33% from the previous trading day, before settling in for the closing price of $20.54. Over the past 52 weeks, BCYC has traded in a range of $12.54-$27.24.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 38.55% over the past five years. While this was happening, its average annual earnings per share was recorded 37.98%. With a float of $65.66 million, this company’s outstanding shares have now reached $68.94 million.
Let’s look at the performance matrix of the company that is accounted for 284 employees. In terms of profitability, gross margin is 83.2%, operating margin of -522.07%, and the pretax margin is -469.25%.
Bicycle Therapeutics Plc ADR (BCYC) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Bicycle Therapeutics Plc ADR is 4.76%, while institutional ownership is 56.17%. The most recent insider transaction that took place on Jul 03 ’24, was worth 4,831. In this transaction CHIEF PROD & SUPPLY CHAIN OFF of this company sold 246 shares at a rate of $19.64, taking the stock ownership to the 22,645 shares. Before that another transaction happened on Jul 03 ’24, when Company’s CHIEF TECHNOLOGY OFFICER sold 967 for $19.64, making the entire transaction worth $18,992. This insider now owns 93,917 shares in total.
Bicycle Therapeutics Plc ADR (BCYC) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 37.98% per share during the next fiscal year.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Trading Performance Indicators
Take a look at Bicycle Therapeutics Plc ADR’s (BCYC) current performance indicators. Last quarter, stock had a quick ratio of 14.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 45.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.81, a number that is poised to hit -0.80 in the next quarter and is forecasted to reach -3.56 in one year’s time.
Technical Analysis of Bicycle Therapeutics Plc ADR (BCYC)
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) saw its 5-day average volume 0.39 million, a positive change from its year-to-date volume of 0.33 million. As of the previous 9 days, the stock’s Stochastic %D was 41.87%. Additionally, its Average True Range was 1.53.
During the past 100 days, Bicycle Therapeutics Plc ADR’s (BCYC) raw stochastic average was set at 93.54%, which indicates a significant increase from 92.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 106.66% in the past 14 days, which was higher than the 63.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.47, while its 200-day Moving Average is $21.28. Nevertheless, the first resistance level for the watch stands at $28.47 in the near term. At $30.59, the stock is likely to face the second major resistance level. The third major resistance level sits at $34.32. If the price goes on to break the first support level at $22.62, it is likely to go to the next support level at $18.89. Assuming the price breaks the second support level, the third support level stands at $16.77.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Key Stats
The company with the Market Capitalisation of 1.82 billion has total of 42,779K Shares Outstanding. Its annual sales at the moment are 26,980 K in contrast with the sum of -180,660 K annual income. Company’s last quarter sales were recorded 9,360 K and last quarter income was -39,810 K.
